Duality Biotherapeutics appoints HUA Haiqing as executive director and names ZHANG Shaoren CFO

Reuters03-23
Duality Biotherapeutics appoints HUA Haiqing as executive director and names ZHANG Shaoren CFO
  • Duality Biotherapeutics said executive director Wen Si resigned from the board and the remuneration committee for personal career development reasons, and will continue as executive director of human resources.
  • Haiqing Hua was appointed an executive director after serving at the company as senior vice president and head of drug discovery, having joined in July 2021 as vice president and head of drug discovery.
  • Hua previously held drug discovery and development roles including principal scientist at Lilly China R&D and work at Shanghai Hansoh BioMedical.
  • Shaoren Zhang was appointed chief financial officer and is currently an executive director and vice president of finance, responsible for the group’s financial strategy, corporate finance, and capital management.
  • Zhang previously worked as a manager at PwC Zhong Tian and served as deputy general manager at Shanghai Yikang Medical Laboratory and Shanghai Shihao International Logistics.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260323-12063540), on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment